MedTrace Logo

Thalidomide in Treating Patients With Thyroid Cancer

NCT00026533 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-06-06

No results posted yet for this study

Summary

RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.

Conditions

Interventions

DRUG

thalidomide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Kenneth Ain

    lead OTHER

Principal Investigators

  • Kenneth Ain, MD · Lucille P. Markey Cancer Center at University of Kentucky

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2003-11-30
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00026533 on ClinicalTrials.gov